Modular Medical, Inc. (NASDAQ: MODD) confirmed that its share price has met Nasdaq Capital Market’s minimum bid‑price requirement. A Nasdaq letter dated April 16, 2026 states that the company’s closing bid price exceeded $1.00 for ten consecutive trading days through April 14, 2026, satisfying Listing Rule 5550(a)(2) and ending the delisting risk that had been looming since a 180‑day extension deadline of December 29, 2025.
The compliance follows a 1‑for‑30 reverse stock split executed on March 26, 2026, which lifted the per‑share price and helped the stock reach the $1.00 threshold. The reverse split was a common strategy for companies whose share price falls below Nasdaq’s minimum, and it was a key factor in the recent price rebound.
While the letter does not comment on Modular Medical’s financial performance, the company remains a development‑stage medical‑device firm focused on insulin delivery. Its Pivot Tubeless Insulin Patch Pump received FDA 510(k) clearance on April 9, 2026, marking a significant milestone that could open a new revenue stream once commercial production begins.
The company has yet to report revenue for the current fiscal year and posted a net loss of $18.82 million for the year ended March 31, 2025. Management has not issued new guidance, but the regulatory compliance and FDA clearance are viewed as positive signals that the company can continue to pursue its commercialization strategy without the immediate threat of delisting.
The Nasdaq compliance letter removes the most immediate regulatory risk for Modular Medical, preserving liquidity and market visibility for investors. The FDA clearance of the Pivot pump adds a forward‑looking product milestone that may improve the company’s long‑term prospects, though the firm remains in the early stages of product development and has not yet generated revenue.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.